Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279549 | 0.89 | TACR1 (0.41) | TACR1BACE1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3977272 | 0.87 | TACR1 (0.43) | TACR1BACE1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL3975619 | 0.81 | NPC1 (0.37) | TACR1BACE1PTGS1LMNAALDH1A1 | |
| SCHEMBL3977057 | 0.79 | PTGS1 (0.42) | PTGS1LMNAALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL4244119 | 0.76 | MGLL (0.44) | LMNAALDH1A1SMN1; SMN2TP53RAB9A | |
| SCHEMBL3981371 | 0.75 | TACR1 (0.38) | TACR1BACE1ALDH1A1POLBGAA | |
| SCHEMBL3980883 | 0.75 | TACR1 (0.37) | TACR1BACE1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL25591913 | 0.74 | ALDH1A1 (0.50) | BACE1LMNAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL6555726 | 0.73 | MAPK8 (0.41) | PTGS1LMNAALDH1A1SMN1; SMN2AR | |
| SCHEMBL3977063 | 0.72 | LMNA (0.45) | PTGS1LMNAALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | TACR1 485/4885BACE1 2433/4885PTGS1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.